Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma
NCT ID: NCT02581878
Last Updated: 2020-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
21 participants
INTERVENTIONAL
2015-11-20
2019-11-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1a
Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (2 mg antibody chelator conjugate \[ACC\]).
BAY1862864
Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
Cohort 1b
Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (10 mg ACC).
BAY1862864
Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
Cohort 2
Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 3.1 MBq (10 mg ACC).
BAY1862864
Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
Cohort 3
Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 4.6 MBq (10 mg ACC).
BAY1862864
Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
Cohort 4
Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 6.1 MBq (10 mg ACC).
BAY1862864
Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BAY1862864
Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* An archival paraffin-embedded tissue or fresh biopsy is available for the retrospective quantitative assessment of CD22 levels
* Bone marrow involvement of cellular marrow with lymphoma determined to be \< 25%
* Subject has failed at least one prior chemo-/immunotherapy-based regimen
* Life expectancy of at least 12 weeks
* Not eligible for, or refused, or failed high-dose therapy combined with autologous stem cell rescue (HDT ASCR)
* Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
* Women of childbearing potential must have negative pregnancy test within seven days before the start of treatment
* Subject was using adequate barrier birth control measures before the study and is willing to continue use of these during the entire course of the study and for the twelve months after the last administration of BAY1862864 Injection
* Adequate bone-marrow, hepatic and renal function
* Subject is capable of giving informed consent and has provided such consent in writing
Exclusion Criteria
* History of anaphylactic reactions to monoclonal antibody therapy. Known or suspected allergy or intolerance to any agent to be given in the course of this study.
* Anti-cancer immunotherapy and/or anti cancer chemotherapy within four weeks before the first dose of study drug
* Previous therapy with fludarabine-containing regimens within three months before screening
* Participation in any other clinical trial in which the subject received active therapy within four weeks before the first scheduled dose of study drug
* Any toxic effects (CTCAE ≥ Grade 2) of previous anti cancer therapy (incl. radiotherapy) that have not yet stabilized or significant post-treatment toxicities have been observed
* Prior definitive radiotherapy completed less than four weeks before the date scheduled for first dose of BAY1862864
* History of symptomatic metastatic brain or meningeal tumors. Presence of new or progressive brain metastases.
* History of clinically significant cardiac disease
* Clinically relevant findings in the ECG.
* Uncontrolled hypertension, defined as systolic blood pressure \> 160 mmHg and / or diastolic blood pressure \> 100 mmHg, despite optimum medical management
* History of arterial or venous thrombotic or embolic events, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis, or clinically relevant pulmonary embolism within three months before the first administration of BAY1862864 (except for adequately treated catheter-related venous thrombosis occurring more than one month before start of study medication)
* Autologous bone-marrow transplant or stem-cell rescue within three months before the first administration of BAY1862864
* Organ allograft (except for corneal transplant) or allogeneic bone-marrow transplant at any time before the first administration of BAY1862864
* Positive result of hepatitis B virus (HBV-DNA) and/or human immunodeficiency virus antibody (HIV-Ab) test
* Liver cirrhosis, defined as Child-Pugh class B or C
* Any active infection of CTCAE Grade ≥2
* Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study
* Major surgery or significant trauma within four weeks before the first administration of BAY1862864
* Any treatment with biological response modifiers (such as, but not limited to, granulocyte colony-stimulating factor, G CSF), or any blood transfusion, within three weeks before first administration of BAY1862864
* Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study result
* Current pregnancy or breast-feeding
* Any condition that is unstable or could jeopardize the safety of the subject and his/her compliance with study requirements
* Close affiliation with the investigation site
* Any use by the subject of illicit drugs or other substances that may, in the opinion of the investigator or his/her designated associate(s), have a reasonable chance of contributing to toxicity or otherwise confound the results
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Skanes Universitetssjukhus
Lund, , Sweden
Southampton General Hospital
Southampton, Hampshire, United Kingdom
Royal Marsden NHS Trust (Surrey)
Sutton, Surrey, United Kingdom
Royal Free Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Linden O, Bates AT, Cunningham D, Hindorf C, Larsson E, Cleton A, Pinkert J, Huang F, Bladt F, Hennekes H, Oedegaardstuen LI, Sturm I, McNamara C. 227Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study. Cancer Biother Radiopharm. 2021 Oct;36(8):672-681. doi: 10.1089/cbr.2020.4653. Epub 2021 Apr 21.
Related Links
Access external resources that provide additional context or updates about the study.
Click here to find results for studies related to Bayer products
Click here to find information about studies related to Bayer Healthcare products conducted in Europe
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-004140-36
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
17845
Identifier Type: -
Identifier Source: org_study_id